{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:16:56Z","timestamp":1777601816485,"version":"3.51.4"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The aim of this study was to investigate the factors affecting plasma valproic acid (VPA) concentration in pediatric patients with epilepsy and the clinical significance of CYP2C9 gene polymorphisms in personalized dosing using therapeutic drug monitoring and pharmacogenetic testing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The medical records of children with epilepsy who underwent therapeutic drug monitoring at our institution between July 2022 and July 2023 and met the inclusion criteria were reviewed. Statistical analysis was performed to determine whether age, sex, blood ammonia, liver function, kidney function, and other characteristics affected the concentration-to-dose ratio of VPA (CDRV) in these patients. To investigate the effect of CYP2C9 polymorphisms on CDRV, DNA samples were collected from patients and the CYP2C9 genotypes were identified using real-time quantitative PCR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean age of 208 pediatric patients with epilepsy was 5.50 \u00b1 3.50 years. Among these patients, 182 had the CYP2C9 *1\/*1 genotype, with a mean CDRV (mcg.kg\/mL.mg) of 2.64 \u00b1 1.46, 24 had the CYP2C9 *1\/*3 genotype, with a mean CDRV of 3.28 \u00b1 1.74, and 2 had the CYP2C9 *3\/*3 genotype, with a mean CDRV of 6.46 \u00b1 3.33. There were statistical differences among these 3 genotypes (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). The CDRV in these patients were significantly influenced by age, aspartate aminotransferase, total bilirubin, direct bilirubin, globulin, albumin\/globulin ratio, prealbumin, creatinine, and CYP2C9 polymorphisms. In addition, multivariate linear regression analysis identified total bilirubin, direct bilirubin, and CYP2C9 polymorphisms as independent risk factors for high CDRV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Liver problems and mutations in the CYP2C9 gene increase VPA levels. This underscores the importance of considering these factors when prescribing VPA to children with epilepsy, thereby enhancing the safety and efficacy of the therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001180","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T08:09:40Z","timestamp":1706602180000},"page":"503-511","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients With Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy"],"prefix":"10.1097","volume":"46","author":[{"given":"Bingsuo","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"},{"name":"School of Pharmacy, Dali University, Yunnan, Dali, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"},{"name":"School of Pharmacy, Dali University, Yunnan, Dali, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"},{"name":"School of Pharmacy, Dali University, Yunnan, Dali, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"},{"name":"School of Pharmacy, Dali University, Yunnan, Dali, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"},{"name":"School of Pharmacy, Dali University, Yunnan, Dali, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingmeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2399-942X","authenticated-orcid":false,"given":"Zijun","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"},{"name":"School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Yunnan, Kunming, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Panzhihua Central Hospital, Sichuan, Panzhihua, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.gtc.2021.08.002","article-title":"How to understand and treat laryngopharyngeal reflux","volume":"50","author":"Snow","year":"2021","journal-title":"Gastroenterol Clin North Am"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1542\/pir.2019-0134","article-title":"Seizures in children","volume":"41","author":"Fine","year":"2020","journal-title":"Pediatr Rev"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"106192","DOI":"10.1016\/j.eplepsyres.2019.106192","article-title":"Epilepsy-related and other causes of mortality in people with epilepsy: a systematic review of systematic reviews","volume":"157","author":"Mbizvo","year":"2019","journal-title":"Epilepsy Res"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"e20192623","DOI":"10.1542\/peds.2019-2623","article-title":"Global burden of childhood epilepsy, Intellectual disability, and sensory impairments","volume":"146","author":"Olusanya","year":"2020","journal-title":"Pediatrics"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"952161","DOI":"10.3389\/fpubh.2022.952161","article-title":"Global, regional, and national burden and attributable risk factors of neurological disorders: the Global Burden of Disease Study 1990\u20132019","volume":"10","author":"Ding","year":"2022","journal-title":"Front Public Health"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5694\/mja17.00951","article-title":"The management of epilepsy in children and adults","volume":"208","author":"Perucca","year":"2018","journal-title":"Med J Aust"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s13760-020-01488-y","article-title":"Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update","volume":"121","author":"Boon","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/archdischild-2022-324427","article-title":"NICE guideline review: epilepsies in children, young people and adults NG217","volume":"108","author":"Jones","year":"2023","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/metabo13010134","article-title":"Therapeutic and toxic effects of valproic acid metabolites","volume":"13","author":"Shnayder","year":"2023","journal-title":"Metabolites"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2710.1999.00202.x","article-title":"Valproate population pharmacokinetics in children","volume":"24","author":"Serrano","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/PEC.0b013e31828ec2d5","article-title":"Valproic acid-induced acute pancreatitis and multi-organ failure in a child","volume":"29","author":"Yaman","year":"2013","journal-title":"Pediatr Emerg Care"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bdd.2328","article-title":"Changes in uridine 5\u2032\u2010diphospho\u2010glucuronosyltransferase 1A6 expression by histone deacetylase inhibitor valproic acid","volume":"43","author":"Sakakibara","year":"2022","journal-title":"Biopharm Drug Dispos"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"112021","DOI":"10.1016\/j.biopha.2021.112021","article-title":"Hidden pharmacological activities of valproic acid: a new insight","volume":"142","author":"Singh","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/fcp.12614","article-title":"Is the mechanism of action of antiseizure drugs a key element in the choice of treatment?","volume":"35","author":"Guery","year":"2021","journal-title":"Fundam Clin Pharmacol"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ntt.2018.11.003","article-title":"Intellectual functioning in clinically confirmed fetal valproate syndrome","volume":"71","author":"Bromley","year":"2019","journal-title":"Neurotoxicol Teratol"},{"key":"R17-20250603","first-page":"e38348","article-title":"Valproate-associated transaminitis and rhabdomyolysis","volume":"15","author":"Sharma","year":"2023","journal-title":"Cureus"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"e12461","DOI":"10.1016\/j.heliyon.2022.e12461","article-title":"Valproic acid induced aplastic crisis and Stevens-Johnson syndrome in a single pediatric patient","volume":"9","author":"Yang","year":"2023","journal-title":"Heliyon"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/ph15010105","article-title":"A 5-year study of lithium and valproic acid drug monitoring in patients with bipolar disorders in an Italian clinical center","volume":"15","author":"Carli","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ejps.2017.10.009","article-title":"Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex","volume":"111","author":"Conner","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/clpt.1990.144","article-title":"Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid","volume":"48","author":"Levy","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.bbalip.2007.01.010","article-title":"Studies on the extra-mitochondrial CoA -ester formation of valproic and Delta4 -valproic acids","volume":"1771","author":"Aires","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0006-2952(03)00076-5","article-title":"The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases","volume":"65","author":"Ethell","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.50.2.259","article-title":"Developmental aspects of human hepatic drug glucuronidation in young children and adults","volume":"50","author":"Strassburg","year":"2002","journal-title":"Gut"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/toxsci\/66.2.185","article-title":"Evaluation of child\/adult pharmacokinetic differences from a database derived from the therapeutic drug literature","volume":"66","author":"Ginsberg","year":"2002","journal-title":"Toxicol Sci"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"846","DOI":"10.21037\/atm-21-1459","article-title":"The association of adjusted plasma valproic acid concentration with CYP2C9 gene polymorphism in patients with epilepsy: a systematic review and meta-analysis","volume":"9","author":"Fang","year":"2021","journal-title":"Ann Transl Med"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0022-3565(24)37076-4","article-title":"Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid","volume":"283","author":"Sadeque","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2217\/pgs-2017-0194","article-title":"Pharmacogenetics of drug\u2013drug interaction and drug\u2013drug\u2013gene interaction: a systematic review on CYP2C9, CYP2C19, and CYP2D6","volume":"18","author":"Bahar","year":"2017","journal-title":"Pharmacogenomics"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/1570159X15666171109143654","article-title":"Relevance of CYP2C9 function in valproate therapy","volume":"17","author":"Monostory","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/1451007","article-title":"Genetic analysis of CYP2C9 with reference to drug response in epilepsy patients of Pakistan","volume":"2022","author":"Maqbool","year":"2022","journal-title":"Genet Res (Camb)"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"599044","DOI":"10.3389\/fped.2020.599044","article-title":"Genetic and non-genetic factors contributing to the significant variation in the plasma trough concentration-to-dose ratio of valproic acid in children with epilepsy","volume":"8","author":"Xu","year":"2020","journal-title":"Front Pediatr"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00228-016-2087-0","article-title":"Impact of age, gender and CYP2C9\/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid: a large-scale study based on naturalistic therapeutic drug monitoring data","volume":"72","author":"Smith","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13049-017-0382-0","article-title":"Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6\/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury","volume":"25","author":"Sun","year":"2017","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40246-023-00461-z","article-title":"Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences","volume":"17","author":"Zhou","year":"2023","journal-title":"Hum Genomics"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"234","DOI":"10.11613\/BM.2022.020707","article-title":"Establishment of gender- and age-specific reference intervals for serum liver function tests among the elderly population in northeast China","volume":"32","author":"Sun","year":"2022","journal-title":"Biochem Med (Zagreb)"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"967614","DOI":"10.3389\/fcvm.2022.967614","article-title":"Blood creatinine and urea nitrogen at ICU admission and the risk of in-hospital death and 1-year mortality in patients with intracranial hemorrhage","volume":"9","author":"Luo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"14","DOI":"10.31083\/j.fbl2801014","article-title":"Pharmaceutical development of intraperitoneal arachis hypogaea as a renal protective agent","volume":"28","author":"Gul","year":"2023","journal-title":"Front Biosci"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bcpt.12776","article-title":"Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity","volume":"121","author":"Zhao","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2006.08.026","article-title":"Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management","volume":"377","author":"Dasgupta","year":"2007","journal-title":"Clin Chim Acta"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/08830738221083480","article-title":"Valproic acid serum concentration and incidence of toxicity in pediatric patients","volume":"37","author":"Young","year":"2022","journal-title":"J Child Neurol"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin Biochem"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/PEC.0b013e31828ec2d5","article-title":"Valproic acid-induced acute pancreatitis and multiorgan failure in a child","volume":"29","author":"Yaman","year":"2013","journal-title":"Pediatr Emerg Care"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/JCP.0000000000001689","article-title":"Valproic acid-associated hyperammonemia: a systematic review","volume":"43","author":"Wong","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13256-020-2343-x","article-title":"Valproate-induced hyperammonemic encephalopathy: a case report","volume":"14","author":"Shah","year":"2020","journal-title":"J Med Case Rep"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1525-139X.2005.18106.x","article-title":"Extracorporeal management of valproic acid toxicity: a case report and review of the literature","volume":"18","author":"Al Aly","year":"2005","journal-title":"Semin Dial"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FTD.0000000000000051","article-title":"Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs","volume":"36","author":"Markoula","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1111\/epi.14446","article-title":"Effect of valproic acid on perampanel pharmacokinetics in patients with epilepsy","volume":"59","author":"Contin","year":"2018","journal-title":"Epilepsia"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1177\/0091270011426875","article-title":"No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers","volume":"52","author":"Cawello","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R51-20250603","first-page":"e45334","article-title":"A case of toxic epidermal necrolysis caused by lamotrigine combined with valproic acid and literature review","volume":"15","author":"Liu","year":"2023","journal-title":"Cureus"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"e0279487","DOI":"10.1371\/journal.pone.0279487","article-title":"Expression of concern: determination of the optimal concentration of valproic acid in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis","volume":"18","year":"2023","journal-title":"PLoS One"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"641512","DOI":"10.3389\/fphar.2021.641512","article-title":"Evaluation of factors impacting the efficacy of single or combination therapies of valproic acid, carbamazepine, and oxcarbazepine: a longitudinal observation study","volume":"12","author":"Peng","year":"2021","journal-title":"Front Pharmacol"},{"key":"R54-20250603","first-page":"516","article-title":"Effect of treatment and additional disease on pharmacokinetic of valproic acid in children with epilepsy","volume":"62","author":"Juarez-Olguin","year":"2010","journal-title":"Rev Invest Clin"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"1037239","DOI":"10.3389\/fphar.2022.1037239","article-title":"Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: effect of ABCB1 gene polymorphism","volume":"13","author":"Shen","year":"2022","journal-title":"Front Pharmacol"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/epi.13011","article-title":"Clinical significance of CYP2C9-status guided valproic acid therapy in children","volume":"56","author":"B\u0171di","year":"2015","journal-title":"Epilepsia"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-020-03080-y","article-title":"Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model","volume":"77","author":"Gu","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10928-013-9323-3","article-title":"Sex related differences on valproic acid pharmacokinetics after oral single dose","volume":"40","author":"Ibarra","year":"2013","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/03602530903209288","article-title":"Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system","volume":"42","author":"Court","year":"2010","journal-title":"Drug Metab Rev"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/FTD.0000000000000778","article-title":"Association between the serum carnitine level and ammonia and valproic acid levels in patients with bipolar disorder","volume":"42","author":"Yokoyama","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/brainsci10100759","article-title":"Chronic valproic acid administration increases plasma, liver, and brain ammonia concentration and suppresses glutamine synthetase activity","volume":"10","author":"Badawy","year":"2020","journal-title":"Brain Sci"},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3122\/jabfm.2007.05.070062","article-title":"Valproate-associated hyperammonemic encephalopathy","volume":"20","author":"Wadzinski","year":"2007","journal-title":"J Am Board Fam Med"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12876-021-01818-1","article-title":"Low preoperative prealbumin predicts the prevalence of complications following liver transplantation","volume":"21","author":"Li","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/1744-9987.13926","article-title":"Associations between liver function parameters and poor clinical outcomes in peritoneal dialysis patients","volume":"27","author":"Song","year":"2023","journal-title":"Ther Apher Dial"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","article-title":"Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype","volume":"94","author":"Kiang","year":"2006","journal-title":"Toxicol Sci"},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3109\/15376516.2010.497977","article-title":"Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients","volume":"20","author":"Amini-Shirazi","year":"2010","journal-title":"Toxicol Mech Methods"},{"key":"R67-20250603","first-page":"63","article-title":"Non-fatal and fatal liver failure associated with valproic acid","volume":"46","author":"Schmid","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"1048728","DOI":"10.3389\/fphar.2022.1048728","article-title":"The serum acylcarnitines profile in epileptic children treated with valproic acid and the protective roles of peroxisome proliferator-activated receptor a activation in valproic acid-induced liver injury","volume":"13","author":"Ma","year":"2022","journal-title":"Front Pharmacol"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"2173498","DOI":"10.1080\/0886022X.2023.2173498","article-title":"A new criteria for acute on preexisting kidney dysfunction in critically ill patients","volume":"45","author":"Hong","year":"2023","journal-title":"Ren Fail"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/17512433.2017.1353418","article-title":"The effect of antiepileptic drugs on the kidney function and structure","volume":"10","author":"Hamed","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0387-7604(94)90003-5","article-title":"Urinary N-acetyl-beta-glucosaminidase and guanidinoacetic acid levels in epileptic patients treated with anti-epileptic drugs","volume":"16","author":"Otsuka","year":"1994","journal-title":"Brain Dev"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00228-020-02872-6","article-title":"Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis","volume":"76","author":"Yoon","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","article-title":"Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes","volume":"3","author":"Ho","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1167.2008.01716.x","article-title":"The clinical impact of pharmacogenetics on the treatment of epilepsy","volume":"50","author":"L\u00f6scher","year":"2009","journal-title":"Epilepsia"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:12:58Z","timestamp":1748970778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001180","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"assertion":[{"value":"2023-09-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}